LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today
that it has appointed Emily Buxton as its Chief Financial Officer. Ms.
Buxton had been serving as the Company's Interim Chief Financial Officer
since October 2012.
President and Chief Executive Officer Brad Mason said, "I am delighted
to announce the appointment of Emily to this critical position,
particularly at this time in Orthofix's history when we are so well
positioned for the future. It will be my pleasure to work side by side
with her and the rest of the executive team as we explore the many
opportunities we have to define the Orthofix of tomorrow. Emily has
successfully served in various financial roles of increasing
responsibility since joining Orthofix in 2003. I believe her proven
track record in financial management, global business experience, and
strong understanding of every aspect of the Company will help take us to
the next level in driving value for our healthcare partners and
shareholders."
Ms. Buxton joined Orthofix's corporate finance group in 2003 as a Senior
SEC and Consolidations Accountant. After advancing to the position of
Vice President, Controller, she served as Chief Financial Officer of
Global Orthopedics for Orthofix from 2010 to the time of her appointment
as Interim Chief Financial Officer. Prior to joining Orthofix, Ms.
Buxton worked for two large public companies in Securities and Exchange
Commission reporting and prior to that she worked in public accounting.
She received her Bachelors of Arts degree in Accounting from Columbia
College in Columbia, SC.
About Orthofix:
Orthofix International N.V. is a diversified, global medical device
company focused on developing and delivering innovative repair and
regenerative solutions to the spine and orthopedic markets. Orthofix's
products are widely distributed around the world to surgeons and
patients via Orthofix's sales representatives and its subsidiaries, and
via collaborations with other leading orthopedic product companies. In
addition, Orthofix is collaborating on R&D activities with leading
research and clinical organizations such as the Musculoskeletal
Transplant Foundation, the Orthopedic Research and Education Foundation,
and Texas Scottish Rite Hospital for Children. For more information
about Orthofix, please visit www.orthofix.com.
Orthofix International N.V.
Mark Quick, 214-937-2924
Director
of Investor Relations and Business Development
markquick@orthofix.com
Source: Orthofix International N.V.
News Provided by Acquire Media